ArticleScience advances2026
A minimal transcription factor network is sufficient to drive paclitaxel biosynthesis.
Article in Science advances, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It has been retracted, and should not be counted. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Editorial expression of concern.Science advances · 2026Article
- Recent advances inFrontiers in plant science · 2026Review
Corrections and comments
- Expression of concern · 2026-08-26Concerns/Issues about Data · Concerns/Issues about Methods · Investigation by Third Party · · see also: https://pubpeer.com/publications/A19DA40360A036D8EE38C5F2D78579
- Expression of concern
Authors and funding
8 authors.
Funding
Abstract
The supply of the anticancer drug paclitaxel is limited by its low natural abundance and complex chemical structure. We previously reported the development of a cultured
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.